Disease · MONDO_0007179
autoimmune disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. autoimmune disease. Diseases, record MONDO_0007179. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007179
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Autoimmune condition, Autoimmunity, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, type II hypersensitivity reaction disease
- Open Targets
Drugs93
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE SODIUM | CHEMBL2106643 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PETESICATIB | CHEMBL4297638 | Small molecule | Phase 2 | TTD | 2 | 0 | 0 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| BIFIDOBACTERIUM SPP. | CHEMBL4297912 | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| BELANTAMAB | CHEMBL4298208 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 93
See all 93 drugsTargets69
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Unknown | https://conductscience.org/library/genes/2908 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 4 | Tyrosine-protein kinase BTK inhibitor | Phase 1 | https://conductscience.org/library/genes/695 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 4 | IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor | Phase 1 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| CD40LG | CD40 ligand | 3 | CD40 ligand antagonist; CD40 ligand inhibitor | Unknown | https://conductscience.org/library/genes/959 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Unknown | https://conductscience.org/library/genes/3716 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Unknown | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Unknown | https://conductscience.org/library/genes/3718 | Drugs and targets |
| ROCK1 | Rho-associated protein kinase | 2 | Rho-associated protein kinase inhibitor | Unknown | https://conductscience.org/library/genes/6093 | Drugs and targets |
1 to 10 of 69
See all 69 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00351377 | Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate | Phase 3 | 111 | 2011-01-12 | Autoimmune Disease | MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT06733935 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Phase 1/2 | 240 | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis | CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01976182 | Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia | Phase 2 | 166 | Large Granular Lymphocytes Leukemia | CYCLOPHOSPHAMIDE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | |
| NCT06557265 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | 120 | Lupus Nephritis, Primary Membranous Nephropathy | CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07509840 | Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency | Phase 3 | 40 | Autoimmune Prematur Ovarian Insuffience | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04665232 | Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases | 18 | Autoimmune Diseases, Infertility | PROGESTERONE | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT07155369 | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | Not applicable | 18 | Systemic Lupus Erythematosus, Systemic Sclerosis | CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06420154 | The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases | Early phase 1 | 9 | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome | CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06373081 | Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease | Not applicable | 6 | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome | CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03886233 | Treatment Outcome of Uveitis in Autoimmune Diseases | 1 | Autoimmune Uveitis | ADALIMUMAB, INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007179
GET https://conductscience.org/api/diseases/v1/MONDO_0007179/drugs?page=2